Two new drugs that can be used to slow the progression of Alzheimer's disease, donanemab and lecanemab, represent a turning point in Alzheimer's research, believes Dr Cath Mummery (UCL Queen Square Institute of Neurology), but she adds they are "just the beginning".
,
Close
